Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

Pediatric Blood and Cancer

Volumn 58, Issue 5, 2012, Pages 815-818

  Kolb, E Anders ^a   Gorlick, Richard ^b   Keir, Stephen T ^c   Maris, John M ^d   Lock, Richard ^e   Carol, Hernan ^e   Kurmasheva, Raushan T ^f   Reynolds, C Patrick ^g   Kang, Min H ^g   Wu, Jianrong ^h   Houghton, Peter J ^f   Smith, Malcolm A ⁱ  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Notch; Preclinical testing

Indexed keywords

GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; RO4929097; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; EVENT FREE SURVIVAL; FEMALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZAZEPINES; CHILD; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863241091     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23290     Document Type: Article

References (18)

1. Liu J, Sato C, Cerletti M, et al. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 2010; 92: 367-409.
2. Imbimbo BP, Panza F, Frisardi V, et al. Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: Still a viable option? Expert Opin Investig Drugs 2011; 20: 325-341.
3. Luistro L, He W, Smith M, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009; 69: 7672-7680.
4. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008; 3: 587-613.
5. Zhang P, Yang Y, Nolo R, et al. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene 2010; 29: 2916-2926.
6. Tanaka M, Setoguchi T, Hirotsu M, et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009; 100: 1957-1965.
7. Engin F, Bertin T, Ma O, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 2009; 18: 1464-1470.
8. Zhang P, Yang Y, Zweidler-McKay PA, et al. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008; 14: 2962-2969.
9. Baliko F, Bright T, Poon R, et al. Inhibition of notch signaling induces neural differentiation in Ewing sarcoma. Am J Pathol 2007; 170: 1686-1694.
10. Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q 33-34 in volved in the progression of childhood ependymomas. J Clin Oncol 2009; 27: 1884-1892.
11. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66: 7445-7452.
12. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-4195.
13. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
14. Houghton PJ, Morton CL, Tucker C, et al. The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
15. DeAngelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006; 24: Abstr #6585.
16. Tolcher AW, Mikulski SM, Messersmith WA, et al. A phase I study of RO 4929 097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2010; 28 (suppl 15; abstr 2502).
17. Yin L, Velazquez OC, Liu ZJ. Notch signaling: Emerging molecular targets for cancer therapy. Biochem Pharmacol 2010; 80: 690-701.
18. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008; 14: 4572-4583.